We read with interest the comments by Willenheimer [1] docardial collagen density decreases with survival duration on our paper recently published in Cardiovascular Re-(from 4.2860.22 for animals deceased between 0 and 3 search [2]. months after coronary ligation down to 2.0160.10 for Willenheimer states that (a) collagen density being the animals deceased between 9 and 12 months after coronary same in untreated MI rats and in irbesartan-treated MI rats, ligation), but in this study the ACE inhibitor trandolapril and (b) heart weight / body weight ratio being decreased in displayed a true antifibrotic effect (collagen density irbesartan-treated vs. untreated MI rats, the absolute 1.4960.26 for rats deceased between 9 and 12 months). myocardial collagen content is reduced in the irbesartanIn summary, even if an apparent antifibrotic effect of treated animals. In our opinion, this assumption is quesirbesartan could be inferred from a reduction in the tionable since fibrosis development is not an evenly absolute myocardial collagen content, we feel that with distributed process. Hence, subendocardial fibrosis (which irbesartan (and in contrast with trandolapril) no true we evaluated) does not necessarily reflect what happens in antagonist effect vs. the pathological process of fibrosis other myocardial layers, and therefore cannot be extrapodevelopment in heart failure was evidenced. lated to the whole myocardium. Now regarding a possible antifibrotic effect of irbesartan, our data show that the pathological process of fibrosis development which is clearly evidenced by the increase of collagen density in References untreated MI rats (5.2660.60) as compared to sham rats (2.1760.09) was neither prevented nor even slightly thus leading to an underestimation of fibrosis in these rats 
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